Fine management of pharmaceutical agents is the key to long-term development of pharmaceutical companies

Over the years, the drug agency model has evolved and innovated. ? Joint development, joint advertising, joint promotion, and proxy sharing form a so-called “mixed mode”. The fine management of pharmaceutical agents is an objective requirement for the sustainable development of pharmaceutical companies, and an important means to break through the homogenization of market competition and improve the core competitiveness of enterprises. With the rapid expansion of sales scale, the power of agents is also rapidly growing. It also enables companies and agents to establish long-term and close cooperative relations, and achieve the purpose of mutual benefit and mutual benefit between drug agents and drug investment enterprises.

First of all, the reason why the drug agency model is adopted by many pharmaceutical companies is that it can help companies use the network and capital resources of local agents to quickly seize the market, expand market share, speed up payment collection, and simplify pharmaceutical agent information in the shortest possible time. Flat channels. Especially for many emerging small and medium-sized pharmaceutical companies focusing on R&D, the funds are limited, there is no network, and there is no market. The investment promotion model can be said to be the preferred mode of operation for quickly occupying the market, rapidly withdrawing funds, and growing rapidly.

Second, with the passage of time, the problem of the drug agency model itself has also increased, manufacturers and agents have a stomach of complaints and frustration. Businesses believe that agents are mixed, terminal control is weak, sales costs grow too fast, and most of the agents attach importance to short-term interests, and it is difficult to cope with the long-term development of the company, and it is difficult to truly become a long-term strategic partner; while agents complain about unstable corporate policies and frequent interventions. And arbitrarily segmented the market, various after-sales services are not in place, and accompanied by increasing costs and risks, drug agent information is full, agents are obviously worried about the company regaining the market, not investment, no action.

Finally, most drug companies and pharmaceutical companies are the first to establish their own promotion teams. The medical device industry, whether it is domestic companies or large-scale foreign companies, has used the investment agency model for the most part and has developed well. Under the guidance of the integrated marketing strategy, through the sales and market management methods such as brand building, agent fine management, professional academic promotion, etc., and the establishment of an increasingly close partnership with the agents, then the investment agent model will be able to achieve mutual benefit and win-win, long-term The long-term goal of development.